High Technology Hospital Medcenter LTD

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Colorectal cancer2 trials
• Triple-negative breast cancer2 trials
• Bladder cancer1 trial
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
• Prostate cancer1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Recruiting4 trials
• Active, not recruiting2 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• BioNTech SE2 trials
• G1 Therapeutics, Inc.2 trials
• Agenus Inc.1 trial
• Amgen1 trial
• argenx1 trial
• and 1 more

Running trials

• Recruiting

  A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

  NCT07540572· Phase 1· IDEAYA Biosciences· Source

  Contact: Mamuka Sikharulidze

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

  Contact: Shorena Vashadze, MD

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

  NCT05608044· Phase 2· Agenus Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Colorectal cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

  NCT04887831· Phase 2· G1 Therapeutics, Inc.· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source